Thyrocare Technologies Limited announced an additional capital infusion of USD 4,75,000 (equivalent to INR 4.33 Crore) into its Tanzanian subsidiary, Thyrocare Laboratories (Tanzania) Limited. This investment was made via subscription to Compulsorily Convertible Irredeemable Preference Shares (CCPS) on February 24, 2026. The purpose is to facilitate ongoing business operations and meet working capital requirements for the healthcare services joint venture.
Capital Infusion in Tanzanian Joint Venture
Thyrocare Technologies Limited has made a further capital investment into its subsidiary, Thyrocare Laboratories (Tanzania) Limited. This strategic move, executed on February 24, 2026, signals continued support for the diagnostic and healthcare services venture established with the Kastipharm Group in Tanzania.
Key Transaction Details
The investment details are as follows:
- Investment Amount: USD 4,75,000 (equivalent to INR 4,32,91,500.00/-).
- Instrument: Subscription to Compulsorily Convertible Irredeemable Preference Shares (CCPS).
- Total Investment to Date: The cumulative investment across all tranches now stands at USD 11,50,020 (equivalent to INR 10,01,62,414/-).
The capital infusion is specifically intended to support Thyrocare Tanzania’s operational needs and working capital requirements. The business remains in the Healthcare Services sector, aligning with the parent company’s core activities.
Shareholding and Transaction Nature
The transaction constitutes a related party transaction. Following this allotment, the percentage of shareholding held by the Company in Thyrocare Tanzania remains 57.25% in Equity Shares, while the CCPS holding now reflects 100.00% post-allotment.
Subsidiary Snapshot (As of December 31, 2025)
Thyrocare Tanzania, incorporated in the Republic of Tanzania on September 19, 2023, has provided limited financial details:
- Turnover: INR 1.84 Crores for the year ended December 31, 2025.
- Net-worth: Negative, standing at INR (0.32) Crores as on December 31, 2025.
The company confirmed that this transaction was carried out at arm’s length, and save for this investment, the promoters/promoter group have no further interest.
Source: BSE
